Skip to main content

Envisioning is an emerging technology research institute and advisory.

LinkedInInstagramGitHub

2011 — 2026

research
  • Reports
  • Newsletter
  • Methodology
  • Origins
  • Vocab
services
  • Research Sessions
  • Signals Workspace
  • Bespoke Projects
  • Use Cases
  • Signal Scanfree
  • Readinessfree
impact
  • ANBIMAFuture of Brazilian Capital Markets
  • IEEECharting the Energy Transition
  • Horizon 2045Future of Human and Planetary Security
  • WKOTechnology Scanning for Austria
audiences
  • Innovation
  • Strategy
  • Consultants
  • Foresight
  • Associations
  • Governments
resources
  • Pricing
  • Partners
  • How We Work
  • Data Visualization
  • Multi-Model Method
  • FAQ
  • Security & Privacy
about
  • Manifesto
  • Community
  • Events
  • Support
  • Contact
  • Login
ResearchServicesPricingPartnersAbout
ResearchServicesPricingPartnersAbout
  1. Home
  2. Research
  3. Helix
  4. Microbiome Analytics Platforms

Microbiome Analytics Platforms

Metagenomic analytics delivering strain-level insights for therapeutics.
Back to HelixView interactive version

Microbiome analytics platforms are cloud-based systems that process shotgun metagenomic sequencing data, metabolomics profiles, and clinical metadata to map the composition and function of microbial communities at strain-level resolution, identifying specific bacterial species and strains and understanding their metabolic capabilities and interactions. These platforms enable biotech companies to design microbial consortia therapies (combinations of beneficial bacteria), monitor the efficacy of fecal microbiota transplantation (FMT), and personalize nutrition interventions based on individual microbiome profiles, creating a foundation for microbiome-based therapeutics and personalized nutrition.

This innovation addresses the complexity of the human microbiome, where understanding which microbes are present and what they do requires sophisticated analysis of vast amounts of sequencing and metabolomic data. By providing comprehensive analytics, these platforms enable the development of microbiome-based therapies and personalized interventions. Companies like Second Genome, uBiome (before its closure), and various research institutions are developing these platforms.

The technology is essential for advancing microbiome-based medicine, where understanding microbiome composition and function is necessary for developing effective therapies. As microbiome research expands, these platforms become increasingly important. However, ensuring accuracy, handling data complexity, and translating insights into actionable interventions remain challenges. The technology represents an important tool for microbiome research and therapeutics, but requires continued development to achieve the accuracy and actionable insights needed for clinical applications. Success could enable new classes of microbiome-based therapies and personalized nutrition, but the field is still relatively early and requires more research to understand optimal applications.

TRL
6/9Demonstrated
Impact
4/5
Investment
4/5
Category
Software

Related Organizations

CosmosID

United States · Company

95%

Provides an industry-leading cloud platform for microbiome analysis using strain-level metagenomics.

Developer
Microba Life Sciences

Australia · Company

92%

Australian precision microbiome company offering analysis services and therapeutic discovery.

Developer
Eagle Genomics

United Kingdom · Company

90%

Applies network science to biology to discover data-driven microbiome insights.

Developer
Clinical Microbiomics

Denmark · Company

88%

Contract research organization specializing in custom microbiome analysis.

Developer
Enterome

France · Company

85%

Clinical stage biopharma company developing immunomodulatory drugs from the gut microbiome.

Deployer
Viome Life Sciences

United States · Company

85%

Focuses on RNA sequencing (metatranscriptomics) to analyze microbial function.

Developer
BiomX logo
BiomX

Israel · Company

80%

A clinical-stage microbiome company developing natural and engineered phage therapies.

Deployer
Metagenomi

United States · Company

80%

Mines the microbiome to discover new gene editing systems.

Developer
BaseClear

Netherlands · Company

75%

Independent laboratory offering microbial genomics and analysis services.

Developer
DNAnexus logo
DNAnexus

United States · Company

70%

Cloud-based biomedical informatics platform.

Developer

Supporting Evidence

Evidence data is not available for this technology yet.

Connections

Applications
Applications
Fecal Microbiota Transplant Banks

Standardized donor screening and cryobanking for microbiome therapies.

TRL
7/9
Impact
4/5
Investment
4/5
Applications
Applications
Postbiotic Metabolite Replacement Therapy

Direct delivery of beneficial gut metabolites to bypass microbiome dysbiosis.

TRL
8/9
Impact
3/5
Investment
3/5
Hardware
Hardware
Portable Multi-Omics Scanners

Handheld metabolomics or proteomics mass-spec devices.

TRL
3/9
Impact
3/5
Investment
3/5
Software
Software
Digital Twin Physiology Platforms

Patient-specific simulation stacks predicting therapy response.

TRL
5/9
Impact
5/5
Investment
4/5

Book a research session

Bring this signal into a focused decision sprint with analyst-led framing and synthesis.
Research Sessions